A single oral 1 mg/kg dose of FTY720 hydrochloride increased bone-marrow CD3, CD4 and CD8 T-cell counts at 24 h in aly/aly mice. This distribution study supports a mechanistic interpretation, without establishing disease-treatment efficacy. [1]
In an independent mouse study using Cayman FTY720 with salt unspecified, oral treatment produced lung S1P1 loss and pulmonary vascular leak, particularly at 5 mg/kg. Both responses were attenuated in internalization-deficient S1P1-S5A mice. This dose- and genotype-dependent adverse finding limits generalizations about receptor downregulation; it does not establish safety for the catalog material. [2]
Bone-marrow T-cell accumulation in alymphoplasia mice
Animal study · Male aly/aly mice, 6–12 weeks, lacking lymph nodes and Peyer’s patches [1]
At 24 h after a single oral FTY720 dose, bone-marrow CD3, CD4 and CD8 T-cell counts were increased compared with control. A separate THI comparator in the same design also increased these counts. Findings support marrow accumulation but do not directly track individual blood cells or distinguish increased entry from decreased egress.
Conditions shared by the study groups
- Route
- Oral
- Frequency
- Single administration
- Treatment course
- 24 h observation
- Vehicle
- Distilled water
- FTY720
- Model: Male aly/aly mice, 6–12 weeks, lacking lymph nodes and Peyer’s patches
- THI comparator
- Model: Male aly/aly mice, 6–12 weeks, lacking lymph nodes and Peyer’s patches
Methods and source locations
Compound reported in the paper: FTY720 (fingolimod); Compound label in the paper: FTY720 hydrochloride, synthesized
Murine lymphocyte-distribution mechanism; neither therapeutic efficacy nor direct S1P1 binding potency is established.
Figure 4 and caption, p190; Results p189; Methods reagents/flow cytometry p187; Discussion p191
Bone-marrow CD3, CD4 and CD8 T-cell counts: Flow cytometry; Student t-test; Figure 4 **p<0.01 — Figure 4 and caption, p190; Results p189; Methods reagents/flow cytometry p187; Discussion p191
FTY720 · Figure 4 and caption, p190; Results p189; Methods reagents/flow cytometry p187; Discussion p191
THI comparator · Figure 4 and caption, p190; Results p189; Methods reagents/flow cytometry p187; Discussion p191
Receptor degradation and pulmonary vascular leak in wild-type and S5A mice
Animal study · Wild-type and internalization-deficient S1P1-S5A knockin mice, 6–8 weeks; C57BL/6 mice listed in animal methods; sex not specified in the selected methods. [2]
Oral FTY720 caused dose-related loss of lung S1P1 and pulmonary dye extravasation. The S5A mutation attenuated both responses. This is evidence connecting receptor regulation to an adverse vascular endpoint, rather than a direct binding assay.
Conditions shared by the study groups
- Route
- Oral gavage
- Frequency
- Single administration
- Treatment course
- 24 h
- Vehicle
- 2% 2-hydoxypropyl-β-cyclodextran in water (source spelling)
- FTY720 0.5 mg/kg
- Model: Wild-type and S1P1-S5A knockin mice
- Reported limits: Exact salt unspecified; dye timing differs between caption and Methods.
- FTY720 5 mg/kg
- Model: Wild-type and S1P1-S5A knockin mice
- Reported limits: Exact salt unspecified; dye timing differs between caption and Methods.
Methods and source locations
Compound reported in the paper: FTY720 (fingolimod); Compound label in the paper: FTY720, Cayman Chemical; salt not specified in paper
Parent-fingolimod literature context only; tested salt unspecified. These mouse dose-response findings do not validate an Adooq lot or predict clinical safety.
Figure 5A–B and caption; Results “FTY720 treatment at a supralymphopenic dose…”; Methods Chemicals and reagents, FTY720 treatment, In vivo vascular permeability assay, Statistics
Lung S1P1 degradation after 24 h: S1P1 immunoblot with β-actin control; Figure 5A n=3, representative experiment repeated 3 times — Figure 5A–B and caption; Results “FTY720 treatment at a supralymphopenic dose…”; Methods Chemicals and reagents, FTY720 treatment, In vivo vascular permeability assay, Statistics
Pulmonary vascular permeability after 24 h: Evans blue dye extravasation; Figure 5B caption n=17 WT and n=7 S5A; mean ± SD; not inferred as n per dose — Figure 5A–B and caption; Results “FTY720 treatment at a supralymphopenic dose…”; Methods Chemicals and reagents, FTY720 treatment, In vivo vascular permeability assay, Statistics
FTY720 0.5 mg/kg · Figure 5A–B and caption; Results “FTY720 treatment at a supralymphopenic dose…”; Methods Chemicals and reagents, FTY720 treatment, In vivo vascular permeability assay, Statistics
FTY720 5 mg/kg · Figure 5A–B and caption; Results “FTY720 treatment at a supralymphopenic dose…”; Methods Chemicals and reagents, FTY720 treatment, In vivo vascular permeability assay, Statistics